The advantages of combining TACE with lenvatinib and tislelizumab remained broadly consistent across a variety of clinical subgroups compared with the TACE-lenvatinib combination, including the subgroups relevant to HCC prognosis, such as age, sex, etiology, baseline tumor burden, and α-fetoprotein (AFP) levels. This evidence concerns the gene AFP and neoplasm.